Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Carasent AB (publ)'s Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was kr15.1 Mil. Therefore, Carasent AB (publ)'s EV-to-EBIT ratio for today is 107.59.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Carasent AB (publ)'s Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr84.7 Mil. Therefore, Carasent AB (publ)'s EV-to-EBITDA ratio for today is 19.16.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Carasent AB (publ)'s Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was kr381.1 Mil. Therefore, Carasent AB (publ)'s EV-to-Revenue ratio for today is 4.26.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Carasent AB (publ) (LTS:0H9M) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Carasent AB (publ)'s current Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr15.1 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Carasent AB (publ)'s current Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr84.7 Mil.
Carasent AB (publ)'s current Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr381.1 Mil.
Carasent AB (publ)'s current Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr95.1 Mil.
Carasent AB (publ)'s current Enterprise Value is kr1,622.4 Mil.
Carasent AB (publ)'s Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr52.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) Enterprise Value Related Terms
Carasent AB (publ) Enterprise Value Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H9M vs VEEV, BTSG, TEM: Enterprise Value Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) Enterprise Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s Enterprise Value distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Carasent AB (publ)'s Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of kr1,622.4 Mil mean?
Carasent AB (publ) (LTS:0H9M) has a Enterprise Value of kr1,622.4 Mil as of Jul. 21, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Carasent AB (publ) and its competitors.
Is Carasent AB (publ)'s Enterprise Value too high?
Carasent AB (publ)'s current Enterprise Value is kr1,622.4 Mil. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s Enterprise Value compare to VEEV and BTSG?
Carasent AB (publ)'s Enterprise Value of kr1,622.4 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Healthcare Providers & Services company?
A good Enterprise Value depends on the Healthcare Providers & Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Carasent AB (publ) and its competitors. Carasent AB (publ)'s current Enterprise Value is kr1,622.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (LTS:0H9M) has a current Enterprise Value of kr1,622.4 Mil. The stock's GF Value™ is kr24.22, compared to a current price of kr20.60 — trading 14.9% below its estimated fair value. The current Enterprise Value is kr1,622.4 Mil. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Carasent AB (publ) (LTS:0H9M), the current Enterprise Value is kr1,622.4 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (LTS:0H9M) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of kr20.60 is trading 14.9% below its estimated GF Value™ of kr24.22.
Key valuation signals for LTS:0H9M:
Enterprise Value: kr1,622.4 Mil
GF Value™: kr24.22 vs. price of kr20.60 (14.9% below fair value)
No single metric tells the full story. See the LTS:0H9M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score
Get the complete analysis for LTS:0H9M
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H9M has been successfully added to your 
